Publications

Corti C, Rugo HS, Tolaney SM. Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2025. PMID: 40367401

Kasap C, Izgutdina A, Patiño-Escobar B, Kang AS, Chilakapati N, Akagi N, Manoj AM, Johnson H, Rashid T, Werner J, Barpanda A, Geng H, Lin YT, Rampersaud S, Gil-Alós D, Sobh A, Dupéré-Richer D, Aleman A, Wicaksono G, Kelii KMK, Dalal R, Ramos E, Vijayanarayanan A, Lakhani K, Salangsang F, Phojanakong P, Camara Serrano JA, Zakraoui O, Tariq I, Chari A, Chung A, Kumar AD, Martin T, Wolf JL, Wong S, Steri V, Shanmugam M, Boise LH, Kortemme T, Parekh S, Stieglitz E, Licht JD, Karlon W, Barwick BG, Wiita A. Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells. Blood. 2025. PMID: 40359480

Khozin S, Dreyer NA, Galante D, Liu R, Neumann P, Nussbaum N, O'Shaughnessy J, Patt D, Rimawi M, Rugo H, Tolaney SM, Weiss M, Brufsky A. Real-World Evidence Acceptability and Use in Breast Cancer Treatment Decision-Making in the United States: Call-to-Action from a Multidisciplinary Think Tank. Advances in therapy. 2025. PMID: 40354012

Vijay V, Karisani N, Shi L, Hung YH, Vu P, Kattel P, Kenney L, Merritt J, Adil R, Wu Q, Zhen Y, Morris R, Kreuzer J, Kathiresan M, Herrera Lopez XI, Ellis H, Gritti I, Lecorgne L, Farag I, Popa A, Shen W, Kato H, Xu Q, Balasooriya ER, Wu MJ, Wan J, Kondo H, Chaturantabut S, Raghavan S, Hall MD, Patnaik S, Shen M, Kelley RK, Cleary JM, Lawrence MS, Root DE, Patra KC, Silveira VS, Benes CH, Deshpande V, Juric D, Sellers WR, Ferrone CR, Haas W, Vazquez F, Getz G, Bardeesy N. Generation of a biliary tract cancer cell line atlas identifies molecular subtypes and therapeutic targets. Cancer discovery. 2025. PMID: 40353839

Ueno NT, Cottone F, Dunton K, Jacot W, Yamashita T, Sohn J, Tokunaga E, Prat A, Tsurutani J, Park YH, Rugo HS, Xu B, Cardoso F, Mitri Z, Mahtani R, Aguilar CO, Xiao F, Harbeck N, Cameron DA, Modi S. Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC. The oncologist. 2025. PMID: 40349139

Muhsen IN, Roloff GW, Faramand RG, Othman T, Valtis YK, Kopmar NE, Dekker SE, Connor M, Mercadal S, O'Connor TE, Dykes KC, Ahmed M, Jeyakumar N, Zhang A, Miller K, Sutherland KC, Guzowski C, Gupta VK, Majhail NS, Battiwalla M, Solh MM, Malik SA, Mathews J, Oliai C, Shaughnessy PJ, Mountjoy L, Lee CJ, Logan AC, Tsai SB, Leonard JT, Schwartz MS, Sasine JP, Kumaran M, Frey NV, Park JH, Koura D, Cassaday RD, Shah BD, Aldoss I, Muffly LS, Hill LC. Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS Involvement. Blood advances. 2025. PMID: 40334068

Othman T, Lo MM, Andreadis CB, Damon LE, Ferng TT, Gaensler KML, Lee JC, Martin TG, Olin RL, Sayre PH, Smith CC, Logan AC. Single-center experience with nelarabine, etoposide, and cyclophosphamide in adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma. Leukemia & lymphoma. 2025. PMID: 40329916

Chi KN, Castro E, Attard G, Smith MR, Sandhu S, Efstathiou E, Roubaud G, Small EJ, de Santana Gomes AP, Rathkopf DE, Saad M, Gurney H, Jung W, Kim W, Dibaj S, Wu D, Zhang J, Lopez-Gitlitz A, Francis P, Olmos D. Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial. European urology oncology. 2025. PMID: 40328571

Schibler B, Spinner M, Naqvi IA, Stein J, Barbuto S. Developing an intensive aerobic exercise program after stroke: A pilot study. PM & R : the journal of injury, function, and rehabilitation. 2025. PMID: 40317613

Pan D, Mouhieddine TH, Sheng T, Fu W, Moshier E, Richter J, Parekh S, Jagannath S, Rossi AC, Sanchez LJ, Thibaud S, Rodriguez C, Cho HJ, Richard S. Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in multiple myeloma. Bone marrow transplantation. 2025. PMID: 40319194

Rugo HS, Bardia A, Gradishar WJ, Hamilton EP, Hurvitz SA, Jhaveri K, Mahtani R, Tolaney SM. Expert consensus on treating HR+/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists. Breast (Edinburgh, Scotland). 2025. PMID: 40344957

Castellanos CX, Lin ME, Gallagher TJ, Swanson MS, Kwon DI. Surgeon Perspectives on Addressing Mental Health Among Total Laryngectomy Patients. Psycho-oncology. 2025. PMID: 40281582

Kwek SS, Yang H, Li T, Ilano A, Chow ED, Zhang L, Chang H, Luong D, Lea A, Clark M, Starzinski A, Shi Y, McCarthy E, Porten S, Meng MV, Ye CJ, Fong L, Oh DY. Identification and regulation of circulating tumor TCR-matched cytotoxic CD4+ lymphocytes by KLRG1 in bladder cancer. JCI insight. 2025. PMID: 40299576

Shah NJ, Sura S, Shinde R, Shi J, Bupathi M, Vickery D, Perini R, Motzer RJ. Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic Renal Cell Carcinoma Post-Immune-Oncology and Vascular Endothelial Growth Factor Receptor Targeted Therapies. Cancers. 2025. PMID: 40361361

Bando H, Takeda Y, Misumi T, Nishikawa T, Wakabayashi M, Yamazaki K, Oki E, Douillard JY, Punt CJA, Koopman M, Van Cutsem E, Bokemeyer C, Venook AP, Lenz HJ, Maehara Y, Andre T, Shi Q, de Gramont A, Yoshino T. Associations between early tumor shrinkage/depth of response and survivals from the ARCAD database. JNCI cancer spectrum. 2025. PMID: 40280867

Trepka KR, Kidder WA, Kyaw TS, Halsey T, Olson CA, Ortega EF, Noecker C, Upadhyay V, Stanfield D, Steiding P, Guthrie BGH, Spanogiannopoulos P, Dumlao D, Turnbaugh JA, Stachler MD, Van Blarigan EL, Venook AP, Atreya CE, Turnbaugh PJ. Expansion of a bacterial operon during cancer treatment ameliorates fluoropyrimidine toxicity. Science translational medicine. 2025. PMID: 40238917

Leyte-Vidal AM, Shah NP. How I individualize treatment for chronic-phase CML. Blood. 2025. PMID: 40239150

Koshkin VS, Schafer JM, Scherrer E, Boyiddle C, Schwartz NRM, Yu H, Fang Q, Baker AF, Sayedian FH, Chan E. Testing and Interpretation of Human Epidermal Growth Factor Receptor 2 Protein Expression and ERBB2 Gene Amplification in Advanced Urothelial Carcinoma. JCO precision oncology. 2025. PMID: 40239139

Huppert LA, Mahtani R, Fisch S, Dempsey N, Premji S, Raimonde A, Jacob S, Quintal L, Melisko M, Chien J, Sandoval A, Carcas L, Ahluwalia M, Harpalani N, Hoppenworth J, Blaes A, Blum K, Kim MO, Idossa D, Rao R, Giridhar KV, Rugo HS. Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC). NPJ breast cancer. 2025. PMID: 40234477

Bergo HC, Leak LB, Bivona TG. Condensates as a Culprit in RAS Activation and Inhibitor Resistance. Cancer research. 2025. PMID: 40053457